Enhanced Recovery After Surgery (ERAS)
Enhanced Recovery After Surgery is a coordinated perioperative pathway that supports recovery through preparation, appropriate anesthesia and analgesia, nutrition, mobilization and complication prevention. The strongest general evidence supports shorter hospital stay and fewer complications; it does not establish a mortality or readmission benefit for every operation. In GU reconstruction, the pathway must also protect the urinary or bowel repair and preserve renal function.[1][2]
See also: Analgesia, Nerve Blocks, Antithrombotic Therapy, Constipation, Frailty.
Building a Procedure-Specific Pathway
A pathway should state what is expected, who is responsible and when the plan needs reassessment. Standardize appropriate care while documenting contraindications and justified departures. A missed process step, a patient-specific exception and a new complication are different audit findings.
| Phase | Core work | Adaptation for reconstruction |
|---|---|---|
| Before surgery | Explain recovery, assess medical/nutritional/function risks, reconcile medication, agree fasting and prophylaxis plans | Discuss catheter, stent, drain or stoma care; assess ability to manage them and available support |
| During surgery | Multimodal analgesia, PONV prevention, normothermia, infection prevention, ventilation and hemodynamic management | Protect kidney and tissue perfusion; select blocks and positioning for the actual operation |
| After surgery | Oral intake as tolerated, supported mobilization, opioid minimization, fluid review and complication surveillance | Retain necessary urinary drainage; distinguish ileus from obstruction or leak |
| After discharge | Clear instructions, supplies, contact route and follow-up | Specify who removes each device, when review/imaging is needed and how to respond to blockage or deterioration |
These domains are a practical structure, not a claim that every guideline contains exactly 21 items or that implementing four items defines a complete ERAS program. The 2026 ERAS Society gynecologic-oncology update is useful for pelvic-surgery planning, but recommendations developed for gynecologic cancer do not automatically apply to every benign urogynecologic or reconstructive procedure.[3]
Preoperative Preparation
- Education and support: explain realistic recovery milestones, pain control and the expected devices. Arrange stoma teaching and marking when relevant.
- Risk assessment: identify frailty, nutritional problems, anemia and unstable disease. Prehabilitation can be offered where appropriate, but its benefit and feasible duration vary; see Frailty.
- Fasting and carbohydrate drinks: avoid unnecessarily prolonged fasting using the anesthesia team's protocol. Carbohydrate loading is a selected intervention, not an instruction for every patient with diabetes, impaired gastric emptying or aspiration risk.
- Medication: agree diabetes, GLP-1, SGLT2, antithrombotic, steroid and chronic analgesic plans before admission. Use the relevant companion workflow rather than applying a generic ERAS medication-hold list.
- Bowel preparation: EAU recommends no preoperative bowel preparation for radical cystectomy. Concomitant colorectal resection has a different pathway; coordinate its preparation and antibiotics with the colorectal team. Pelvic location alone does not justify bowel preparation.[2][3][12]
Anesthesia and Analgesia
Agree an opioid-sparing plan appropriate to the incision, renal function, bleeding risk and prior opioid exposure. Acetaminophen, suitable anti-inflammatory therapy, local infiltration and selected regional techniques can reduce opioid requirements. Epidural or spinal analgesia is not mandatory for every ERAS operation, and local-anesthetic combinations require dose and compatibility checks. Use Analgesia and Nerve Blocks for the actual choices and monitoring.[3][12]
Provide PONV prevention before symptoms occur, maintain temperature, use appropriate antimicrobial prophylaxis/redosing, and monitor ventilation and neuromuscular recovery. Manage glucose using the patient's perioperative diabetes pathway; avoid both hypoglycemia and uncontrolled hyperglycemia. A generic ERAS table should not replace these more specific protocols.
Fluid and Hemodynamic Management
Aim for adequate circulating volume and organ perfusion while avoiding overload. Do not impose a universal intraoperative net-fluid ceiling of 30 mL/kg, or discontinue IV support solely because 24 hours have elapsed. Evaluate blood loss, vasodilation, fluid responsiveness, cardiac/renal function and ongoing losses; reduce IV fluids as oral intake and clinical stability permit.[4][12]
The RELIEF trial randomized 3,000 higher-risk major-abdominal-surgery patients; 2,983 entered its modified intention-to-treat analysis. A restrictive regimen did not improve one-year disability-free survival and increased acute kidney injury (8.6% versus 5.0%). The study included urologic/renal operations but was not a reconstructive-specific trial. Its findings caution against excessive restriction; they also do not justify indiscriminate fluid loading.[4]
A 2026 post hoc RELIEF follow-up found no significant difference in new or progressive stage ≥3 CKD between restrictive and liberal groups (56.0% versus 53.4%; adjusted OR 1.13, 95% CI 0.91–1.41). Follow-up was available for 1,670 of the original 2,983 participants, with 1,520 in the primary kidney analysis. This incomplete long-term follow-up does not establish equivalence or negate the original acute kidney injury finding.[13]
Goal-directed monitoring may assist selected major operations, but it is not a guarantee of better outcomes. In OPTIMISE II, 2,498 eligible older gastrointestinal-surgery patients were studied after four age-ineligible enrolments were excluded. Cardiac-output-guided fluids plus fixed low-dose inotrope infusion, chiefly dobutamine, did not reduce 30-day infection (23.2% versus 22.7%) and increased acute cardiac events within 24 hours (3.0% versus 1.7%), mainly arrhythmias. This tests a specific combined algorithm, not every use of individualized hemodynamic monitoring.[5]
Postoperative Recovery
Nutrition and Mobilization
Offer early oral intake and supported mobilization when clinically appropriate. Colorectal and gynecologic guidance support a regular diet within 24 hours in uncomplicated recovery, including suitable bowel-resection patients. Adjust for vomiting, obstruction, aspiration risk, hemodynamic instability or another complication. Review nutrition support when intake remains inadequate; use Nutrition.[3][12]
Mobilization requires adequate analgesia, hemodynamic tolerance and practical assistance. Set achievable goals with nursing and therapy staff; investigate an unexpected decline rather than recording it only as poor compliance. Older adults may need delirium prevention, sensory aids and additional discharge support.
Catheters, Drains and Nasogastric Tubes
Avoid devices without an indication and remove them when their purpose has ended. A catheter protecting a urethral anastomosis, bladder repair, fistula repair or new reservoir is not an unnecessary routine catheter. Specify drainage and imaging plans by the reconstruction. Similarly, an indicated drain or therapeutic nasogastric tube should not be removed merely to satisfy a generic early-removal target.[2][3][12]
The 2026 gynecologic guideline distinguishes routine early bladder-catheter removal from injury and complex reconstruction. Use the dedicated operative/trauma guidance for the latter, particularly after radiation; there is no single catheter-removal day for all GU repairs.[3]
Bowel Recovery and Alvimopan
Prevent avoidable opioid exposure, dehydration and electrolyte disturbances. New distension or vomiting requires assessment for ileus, obstruction, leak or infection rather than automatic escalation of laxatives. See Constipation.
Alvimopan's US indication is gastrointestinal recovery after partial bowel resection with primary anastomosis, not “open radical cystectomy” as a stand-alone labeled indication. Treatment begins before surgery and is limited to inpatient short-term use under its REMS. Therapeutic opioid use for more than seven consecutive days immediately beforehand is a contraindication.[7]
The pivotal cystectomy trial randomized 280 patients, with 277 in the primary modified intention-to-treat analysis; it improved bowel recovery and hospital stay in a setting largely involving open surgery and postoperative IV opioids. Its incremental benefit in a modern low-opioid minimally invasive pathway may differ. Doses and label limits remain in the pharmacology companion.[8]
VTE Prevention
Combine procedure-specific thrombosis risk with patient factors, bleeding risk and neuraxial constraints. EAU recommends pharmacologic prophylaxis after radical cystectomy, starting the first postoperative day and continuing for at least four weeks. This does not create a four-week anticoagulation rule for every pelvic reconstruction. European urology guidance distinguishes ambulatory surgery, prostate surgery/lymph-node dissection and cystectomy. Use Antithrombotic Therapy for selection, timing and duration.[2][6]
Discharge Readiness
Discharge depends on a stable clinical course, an achievable oral treatment plan, suitable intake/mobility, safe device care, help where needed and a clear route back to care. Same-day discharge may be feasible in selected operations and patients; an ERAS label does not establish a universal >90% same-day rate for prostatectomy or nephrectomy. Do not treat a longer stay for a complication or unmet support need as pathway failure alone.
What Outcomes Are Supported?
| Evidence | Main finding | Interpretation |
|---|---|---|
| Sauro 2024 meta-analysis: 74 RCTs | Hospital stay shorter by 1.88 days in 44 trials; 30-day complications RR 0.71 in 14 trials | Substantial heterogeneity; only two included trials were urologic |
| Same meta-analysis: 30-day readmission and mortality | Readmission RR 1.04 (95% CI 0.81–1.35); mortality RR 0.95 (0.48–1.88), each from 19 trials | No demonstrated reduction; this is not proof of equivalence |
| Cochrane 2022 gynecologic cancer review: seven RCTs, 747 participants | Possible shorter stay and fewer readmissions; low-certainty evidence | Not evidence of mortality benefit or the same effect in benign GU reconstruction |
| POWER colorectal cohort: 2,084 patients | Higher adherence associated with fewer complications | Observational association; postoperative illness can itself prevent adherence |
The 2024 review was not a 142-study randomized analysis and did not confirm benefits for every listed outcome. Pooled effects depend on the operation, baseline care, bundle and study quality. Avoid giving a universal promise of a 30–50% reduction in stay, a fixed dollar saving or preserved long-term oncologic outcomes from an ERAS bundle.[1][9][11]
For augmentation, complex urethroplasty, benign diversion and fistula repair, borrow suitable recovery principles while auditing the relevant endpoints: renal complications, bowel dysfunction, leak, infection, readmission, device management, functional recovery and patient experience. Do not transfer colorectal or gynecologic effect sizes unchanged.
Implementation and Audit
- Agree a written operation-specific pathway with surgery, anesthesia, nursing, nutrition and therapy teams.
- Name a coordinator and assign responsibility for each phase, including post-discharge problems.
- Integrate recovery discussions into safety checks. The 2023 Delphi ERAS surgical checklist provides prompts before induction, incision and leaving the operating room. It is a consensus implementation tool; its development study did not prove improved patient outcomes.[10]
- Record each applicable element, including reasons it was not used. The 2026 gynecologic guideline proposes ≥80% overall compliance; this is a program target in that context, not a biological threshold or a reason to override a contraindication.[3]
- Audit both process and outcomes. Review pain, nausea, oral intake, mobilization, kidney injury, bowel recovery, infection, thrombosis, readmission and patient-reported recovery. Separate improvement over time from changes in case mix or discharge resources.
References
1. Sauro KM, Smith C, Ibadin S, et al. Enhanced Recovery After Surgery Guidelines and Hospital Length of Stay, Readmission, Complications, and Mortality: A Meta-Analysis of Randomized Clinical Trials. JAMA Netw Open. 2024;7:e2417310. doi:10.1001/jamanetworkopen.2024.17310. Figure correction.
2. European Association of Urology. Muscle-invasive and Metastatic Bladder Cancer guideline: perioperative care and radical cystectomy recommendations. 2026. Official guideline.
3. Nelson G, Altman AD, Metcalfe A, et al. Enhanced Recovery After Surgery (ERAS®) Society Guidelines for Gynecologic Oncology: 2026 Update. Gynecol Oncol. 2026;210:153–173. doi:10.1016/j.ygyno.2026.05.022.
4. Myles PS, Bellomo R, Corcoran T, et al. Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery. N Engl J Med. 2018;378:2263–2274. doi:10.1056/NEJMoa1801601.
5. OPTIMISE II Trial Group. Cardiac Output-guided Haemodynamic Therapy for Patients Undergoing Major Gastrointestinal Surgery: OPTIMISE II Randomised Clinical Trial. BMJ. 2024;387:e080439. doi:10.1136/bmj-2024-080439.
6. Tikkinen KAO, et al. European Guidelines on Peri-operative Venous Thromboembolism Prophylaxis: First Update. Chapter 12: Urology. Eur J Anaesthesiol. 2024. Full text.
7. Alvimopan. US prescribing information. DailyMed.
8. Lee CT, Chang SS, Kamat AM, et al. Alvimopan Accelerates Gastrointestinal Recovery After Radical Cystectomy: A Multicenter Randomized Placebo-controlled Trial. Eur Urol. 2014;66:265–272. doi:10.1016/j.eururo.2014.02.036.
9. Ripollés-Melchor J, Ramírez-Rodríguez JM, Casans-Francés R, et al. Association Between Use of Enhanced Recovery After Surgery Protocol and Postoperative Complications in Colorectal Surgery: The POWER Study. JAMA Surg. 2019;154:725–736. doi:10.1001/jamasurg.2019.0995.
10. Pilkington M, Nelson G, Cauley C, et al. Development of an Enhanced Recovery After Surgery Surgical Safety Checklist Through a Modified Delphi Process. JAMA Netw Open. 2023;6:e2248460. doi:10.1001/jamanetworkopen.2022.48460.
11. Chau JPC, Liu X, Lo SHS, et al. Perioperative Enhanced Recovery Programmes for Women With Gynaecological Cancers. Cochrane Database Syst Rev. 2022;3:CD008239. doi:10.1002/14651858.CD008239.pub5.
12. Irani JL, Hedrick TL, Miller TE, et al. Clinical Practice Guidelines for Enhanced Recovery After Colon and Rectal Surgery From ASCRS and SAGES. Dis Colon Rectum. 2023;66:15–40. doi:10.1097/DCR.0000000000002650.
13. McIlroy DR, Wallace SK, Forbes A, et al. Perioperative Intravenous Fluid and Chronic Kidney Disease: Long-Term Follow-Up of the Restrictive Versus Liberal Fluid Therapy in Major Abdominal Surgery (RELIEF) Randomised Trial. Br J Anaesth. 2026;137:479–489. doi:10.1016/j.bja.2026.05.010.